---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-190800"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2023-07-21T23:59:59+00:00"
generated_at: "2026-06-13T04:50:46.850230+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio closes $40M registered direct offering of common stock and warrants

## Summary
- Issued 14,569,296 shares at $2.7455 per share with warrants for 14,569,296 shares at $3.2946.
- Gross proceeds of ~$40M before fees; Jefferies as placement agent at 6% fee.
- Warrants are immediately exercisable and expire 3 years from issuance.
- Closing expected July 25, 2023, subject to customary conditions.
- February 2023 warrants amended to match new warrants' exercise price and 3-year term.

## SEC filing metadata
- accession: 0001193125-23-190800
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2023-07-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000119312523190800/0001193125-23-190800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000119312523190800/d489429d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-190800
- JSON: https://secwatch.observer/filing/0001193125-23-190800.json
- Plain text: https://secwatch.observer/filing/0001193125-23-190800.txt

## Key facts
- Material Agreements
  ImmunityBio, Inc. entered into stock purchase agreement (the “SPA”) with certain institutional investors (the “Investors”) valued at approximately $40.0 million (effective 2023-07-20).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors (the “Investors”)
  - Value: approximately $40.0 million
  - Effective: 2023-07-20
  source text: On July 20, 2023, ImmunityBio, Inc. (the “Company”) entered into a stock purchase agreement (the “SPA”) with certain institutional investors (the “Investors”) for the purchase and sale of 14,569,296 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and warrants to purchase an additional 14,569,296 shares of Common Stock at an exercise price of $3.2946 per share, for a purchase price of $2.7455 per share and accompanying warrant, generating gross proceeds from the offering of approximately $40.0 million before deducting placement agent fees and other estimated offering expenses (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000119312523190800/0001193125-23-190800-index.htm
- Material Agreements
  ImmunityBio, Inc. entered into placement agency agreement (the “PAA”) with Jefferies LLC (the “Placement Agent”) (effective 2023-07-20).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC (the “Placement Agent”)
  - Effective: 2023-07-20
  source text: On July 20, 2023, the Company also entered into a placement agency agreement (the “PAA”) with Jefferies LLC (the “Placement Agent”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000119312523190800/0001193125-23-190800-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.